Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 May 19;32(24):2829-32. doi: 10.1016/j.vaccine.2014.02.029. Epub 2014 Mar 2.

Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors.

Author information

1
Laboratório de Imunologia Viral, Instituto Butantan, Av. Vital Brazil 1500, 05503-900 São Paulo, Brazil.
2
Laboratório de Imunologia Viral, Instituto Butantan, Av. Vital Brazil 1500, 05503-900 São Paulo, Brazil. Electronic address: carlos.pereira@butantan.gov.br.

Abstract

The present study shows the humoral and cellular aspects of immune response generated by a recombinant rabies virus glycoprotein (rRVGP) as compared to those generated by viral vector carrying the RNA coding for this protein (RVGP-RNA). The rRVGP was synthesized by stably transfected Drosophila melanogaster Schneider 2 (S2) cells and the RVGP-RNA was carried by a recombinant Semiliki Forest Virus (SFV-RVGP). The data show that protein as well as the RNA vaccine was capable of inducing reasonably acceptable levels of antibodies as compared to the optimized commercial whole virus vaccine. As expected, the RNA vaccine was clearly more effective than the protein vaccines in inducing a cellular immune response, as evaluated by the IgG2a/IgG1 ratio and synthesis of interferon gamma (IFNγ) and interleukin 2 (IL2). Our study supports the importance of vaccine designing taking into consideration the concept of DNA/RNA ability to induce an effective cell immune response.

KEYWORDS:

Immune response; Protein; RNA; Rabies; Vaccine

PMID:
24598721
DOI:
10.1016/j.vaccine.2014.02.029
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center